We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SYGNIS Granted European and US Patent for Drug Screening Platform
News

SYGNIS Granted European and US Patent for Drug Screening Platform

SYGNIS Granted European and US Patent for Drug Screening Platform
News

SYGNIS Granted European and US Patent for Drug Screening Platform

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SYGNIS Granted European and US Patent for Drug Screening Platform"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SYGNIS Pharma AG has been granted the European and US patent for a new basic technology for the detection of protein-protein interactions, a screening platform for the development of novel drugs.

In the words of SYGNIS’ CEO, Pilar de la Huerta, “the technology will be licensed to a distribution partner and we expect to see our first revenues during the current financial year 2013.”

Protein-protein interactions falls within the scope of proteomics, a field that is growing in importance for research into new customized drugs.

SYGNIS’ new platform can be used to improve the characterization of new drugs in development and identification of new therapeutic targets.

SYGNIS’ technology will increase the potential for generating better drugs within the customized drug development field. Following its merger with the Spanish company X-Pol, which forms part of the GENETRIX Group, SYGNIS aims to become a key player in the growing market for molecular tools and personalized medicine.

SYGNIS aims to use these patents, together with its recent company restructuring and successful implementation of the polymerase QualiPhi™, to enhance the impetus it announced on its merger with X-Pol and become a prominent player in the growing market for new DNA tools and customized drugs, a sector that has seen a two-digit growth rate over the last few years.

According to sources from SYGNIS, this transformation will enable it to obtain its first revenues in 2013 and operating profit in successive years.

Advertisement